Cefozopran CAS 113359-04-9
Introduction：Basic information about Cefozopran CAS 113359-04-9, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
Cefozopran Basic information
| Product Name: | Cefozopran |
| Synonyms: | CEFOZOPRAN;sce2787;SCE2787;SCE 2787;Cefozopran(SCE 2787);1-[[(6R,7R)-7-[[(2Z)-(5-Amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-imidazo[1,2-b]pyridazinium hydroxide inner salt;1-[[(6R,7R)-7-[[2Z)-(5-Amino-1,2,4-thiadiazol-3-yl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]imidazo[1,2-b]pyridazinium Inner Salt;Firstci;SCE-1787 |
| CAS: | 113359-04-9 |
| MF: | C19H17N9O5S2 |
| MW: | 515.52 |
| EINECS: | 601-249-3 |
| Product Categories: | Antibacterial;Intermediates & Fine Chemicals;Pharmaceuticals;Cefozopran Hydrochloride and its intermediates |
| Mol File: | 113359-04-9.mol |
Cefozopran Chemical Properties
| Melting point | >300°C |
| storage temp. | Store at -20°C |
| solubility | Soluble in DMSO |
| InChIKey | QDUIJCOKQCCXQY-RWDKEWRNNA-N |
| SMILES | C(C1=C(CS[C@]2([H])[C@H](NC(=O)/C(/C3N=C(N)SN=3)=N\OC)C(=O)N12)C[N+]1C=CN2N=CC=CC=12)(=O)[O-] |&1:5,7,r| |
| CAS DataBase Reference | 113359-04-9(CAS DataBase Reference) |
Safety Information
| Chemical Properties | White To Pale-Yellow Powder |
| Uses | Antibacterial |
| Definition | ChEBI: Cefozopran is a fourth-generation cephalosporin antibiotic having imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively. It is a cephalosporin, a member of thiadiazoles and an imidazopyridazine. |
| Antimicrobial activity | An aminothiazole cephalosporin formulated as the hydrochloride.Activity is similar to that of ceftazidime, but it is moreactive against methicillin-susceptible staphylococci (MIC 1mg/L). Representative MICs against Gram-negative speciesare: Esch coli 0.25 mg/L; K. pneumoniae 1 mg/L; Ps. aeruginosa1–8 mg/L. Activity against Acinetobacter spp., Sten. maltophiliaand B. fragilis group is poor. A 20-min infusion of 1.5 g achieved a plasma concentrationof around 125 mg/L at the end of infusion. Almost 90%of the dose was excreted in the urine over 24 h. The mean terminalhalf-life was around 2 h. Adverse reactions appear to betypical of those of other group 6 cephalosporins. It is available in Japan. |
| in vivo | Cefozopran (SCE-2787) (5-80 mg/kg; s.c.; twice a day for 5 days; four-week-old ICR male mice) is effective against acute respiratory tract infections caused by Kiebsiella pneumonia DT-S. In the model of chronic respiratory tract infection caused by K. pneumoniae 27, Cefozopran (20-80 mg/kg; s.c.; twice a day for 7 days; five-week-old CBA/J female mice) is as effective as Ceftazidime[2]. |
| IC 50 | β-lactam |
Cefozopran Preparation Products And Raw materials
| Raw materials | Ethyl acetate-->Dichloromethane-->Hexane-->Trifluoroacetic acid-->Phosphorus pentachloride-->Potassium iodide-->2-Butanone-->Formamide-->2-Mercapto-5-methyl-1,3,4-thiadiazole-->Pyridazine |
